Savara Announces New Employment Inducement Grant - August 20, 2026
Savara Inc. announced inducement grants to eight new employees, consisting of options to purchase 74,500 shares and restricted stock units (RSUs) covering 64,500 shares. These awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, in accordance with NASDAQ Listing Rules, to attract and retain talent. The options have a 10-year term and vest quarterly, while RSUs vest fully on the two-year anniversary of employment, all subject to continued employment.
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11
This article provides an overview of recent analyst ratings for Savara (SVRA.US), highlighting that analysts forecast a price target between $9 and $11. It compiles a consensus based on ratings from Wall Street analysts, offering investors insight into expert opinions on the stock's potential performance.
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA
Walleye Capital LLC has initiated a new position in Savara Inc. (NASDAQ:SVRA) by acquiring 248,720 shares valued at approximately $1.53 million during the second quarter. Despite mixed analyst sentiment, with a "Moderate Buy" consensus but recent downgrades, institutional investors collectively hold 87.93% of the company. Savara reported a quarterly loss exceeding expectations, and analysts project continued losses for the foreseeable future.
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Savara (NASDAQ:SVRA) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Moderate Buy" with a $10.14 price target. The company recently reported a quarterly loss of $0.16 per share, missing expectations, and analysts have lowered earnings forecasts through 2030, projecting continued losses before eventual profitability. Institutional investors hold a significant 87.93% stake in the clinical-stage biopharmaceutical company.
HC Wainwright Brokers Lower Earnings Estimates for Savara
HC Wainwright has lowered its Q3 2026 earnings per share estimate for Savara to a loss of $0.16, down from $0.15, and projects full-year losses through 2028. This adjustment follows Savara's Q2 earnings report, where the company missed consensus estimates with a loss of $0.16 per share. Despite these revised estimates, analysts maintain a "Moderate Buy" rating for Savara with an average price target of $10.14, while institutional investors hold a significant 87.93% stake in the clinical-stage biotech firm.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for potential share dilution, primarily for an ESOP-related offering. Despite this, the company's investment narrative remains closely tied to the upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are advised to weigh the dilution risk against the potential impact of these regulatory outcomes.
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings
HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a quarterly loss of $0.16 per share, missing analyst consensus, but its shares rose 2.3% to $5.70.
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary
Savara Inc reported a net loss of $(40.2M) and an EPS of $(0.16) for Q2 2026, widening its loss compared to the previous year. As a pre-revenue biopharma company, its financial highlights showed increased losses while business highlights focused on regulatory milestones, clinical progress for MOLBREEVI, and commercial readiness for potential product launches in key markets. The company also continues to invest in R&D and manufacturing to support future supply and regulatory approval.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are weighing the dilution risk against the potential upside from these regulatory outcomes.
SAVARA Q2 EPS USD -0.16
The article reports that Savara (SVRA) announced its Q2 Earnings Per Share (EPS) as USD -0.16. This financial figure indicates the company's profitability during the second quarter.
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Savara (NASDAQ:SVRA) announced its quarterly earnings, reporting a loss of $0.16 per share, which missed the consensus estimate by $0.02. Shares fell by $0.16 to $5.57 during Tuesday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $10.14.
Savara Extends MOLBREEVI Patent Protection to 2041
Savara Inc. has secured patent protection in Europe and Australia for its investigational lung-disease therapy, MOLBREEVI, extending coverage to March 2041. These patents cover the liquid formulation and add to existing protection for the drug-device combination, strengthening the company's intellectual property portfolio in markets without approved alternatives. MOLBREEVI, an orally inhaled GM-CSF therapy, has received Fast Track, Breakthrough Therapy, and Orphan Drug designations from the FDA for autoimmune pulmonary alveolar proteinosis.
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in Savara Inc. (NASDAQ:SVRA) during the first quarter, purchasing an additional 320,572 shares to own a total of 652,672 shares valued at approximately $3.56 million. Other institutional investors also modified their holdings, with hedge funds and institutions collectively owning 87.93% of Savara's outstanding stock. Analysts maintain a "Moderate Buy" rating for Savara, with an average price target of $10.14, despite the company reporting a quarterly loss of $0.15 per share, slightly missing expectations.
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Savara Inc (SVRA), detailing its current earnings forecast score, analyst ratings, and price targets. Eight analysts have given Savara Inc an average price target of $10.25, with a majority recommending a "Buy." The report also includes recent and projected EPS figures for the company.
Savara (SVRA) to Announce Quarterly Earnings on Wednesday
Savara (NASDAQ:SVRA) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $0.14 per share on revenue of $2.00 million, with the earnings call set for August 11th at 4:00 PM ET. The company's lead candidate, Molgradex, is currently under regulatory review for autoimmune pulmonary alveolar proteinosis.
Savara investors brace for earnings ahead of crucial FDA review By Investing.com
Savara Inc. is set to report second-quarter earnings, with analysts expecting a loss of $0.145 per share. The clinical-stage biotech company is preparing for a crucial FDA decision on its lead drug candidate, molgramostim, for which it has a PDUFA date set for November 22, 2026. Investors are closely watching the company's cash position, burn rate, and progress on commercial infrastructure ahead of the potential approval.
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA)
This article revisits Savara Inc. (SVRA), focusing on its APAP BLA filing progress and identifying the upcoming APAP BLA PDUFA as a pivotal near-term catalyst. The author, who previously rated Savara as a "Buy," highlights the company's clinical and regulatory milestones as key investment drivers. The investment thesis centers on SVRA's execution and regulatory pathway for APAP, with a focus on monitoring the launch of MOLBREEVI if approved.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of their management team will host one-on-one meetings and a fireside chat on June 3rd, 2026. A live webcast and replay of the event will be available on the company's corporate website.
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA
Seven Fleet Capital Management LP significantly increased its stake in Savara Inc. (NASDAQ:SVRA) by 371.1% in the first quarter, now owning 295,688 shares valued at $1.61 million. This move is part of a broader trend of institutional investment, with such entities collectively holding 87.93% of the company. Despite Savara missing its quarterly earnings estimates, analysts maintain a "Moderate Buy" rating with a consensus price target suggesting significant upside from its current trading price.
Levi & Korsinsky Urges Savara Inc. (SVRA) Shareholders to Act Before Lead Plaintiff Deadline November 7, 2025
Levi & Korsinsky is urging shareholders of Savara Inc. (SVRA) who suffered losses between March 4, 2024, and May 23, 2025, to act before the lead plaintiff deadline of November 7, 2025. A class action lawsuit alleges that Savara Inc. made false and misleading statements regarding the regulatory approval of its drug MOLBREEVI and potential capital needs. Shareholders can visit the firm's website or contact Joseph E. Levi to learn more about their rights to seek recovery.
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Savara Inc. announced that the European and Australian Patent Offices have granted patents for the liquid formulation of MOLBREEVI, providing intellectual property protection until March 2041 in both regions. These patents strengthen Savara's position in ex-US markets for its investigational drug, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (PAP). The company is also pursuing similar patent filings in the U.S., including for the drug-device combination.
SVRA|Savara Inc|Price:5.435|Chg%:-0.075
This article provides a comprehensive stock analysis of Savara Inc (SVRA) from TradingKey, highlighting its relatively weak fundamentals but high growth potential and fairly valued status within the Biotechnology & Medical Research industry. Key insights include very high institutional ownership, recent "Buy" ratings from analysts with a target price of $10.94, and an expected upward trend in the medium term despite recent weak market performance. The company specializes in rare respiratory diseases, with its lead program, molgramostim inhalation solution (MOLBREEVI), in Phase III development.
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, the stock's price momentum score is 3.86, and it is trading between a resistance level of $6.12 and a support level of $4.89. The analysis recommends a neutral stance, noting more sell signals from moving averages despite some oversold indicator readings.
Savara Inc (SVRA) Institutional Confidence
Savara Inc (SVRA) has an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 16.97% quarter-over-quarter to 104.36%. Key institutional shareholders include New Enterprise Associates (NEA), Bain Capital Life Sciences Investors, LLC, and VR Adviser, LLC.
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis
Savara Inc (SVRA) currently holds a financial score of 5.22, placing it low within the Biotechnology & Medical Research industry (373 out of 386). The analysis indicates weak financial status and low operating efficiency for the company. Key financial components such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not been fully disclosed by the company.
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Savara Inc (SVRA), listing major shareholders and their proportional holdings. It also breaks down shareholding by type, such as investment advisors and hedge funds, and provides a historical view of institutional shareholdings and recent shareholder activity. Additionally, it lists several ETFs that include SVRA in their portfolios.
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information on Savara Inc (SVRA)'s dividend history and stock splits. It states that Savara Inc has not distributed any dividends over the past 5 years. While it offers a table for dividend dates, no data is currently available.
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking 63rd in its industry. Analysts have set an average price target of $10.25, with a majority recommending a "Buy" for the stock. The company's recent EPS was -$0.13, beating market expectations of -$0.15, with the next quarter's EPS expected at -$0.14.
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA
This article provides a financial overview of Savara, Inc. (NASDAQ: SVRA) by detailing its revenue breakdown. It lists various financial data points like statements, statistics, dividends, earnings, and segments. The content also mentions the sources of market and reference data used.
Savara Inc (SVRA) Cash Flow
This article provides a detailed cash flow statement for Savara Inc (SVRA), offering both quarterly and annual data for operating, investing, and financing activities. It breaks down various components such as net income from continuing operations, capital expenditures, and net cash flow from common stock issuance. The article also includes a FAQ section defining different types of cash flow and Savara Inc's performance in each category.
Form 4 Savara Inc For: 24 July By Investing.com
This article announces the filing of a Form 4 for Savara Inc. on July 24, as reported by Investing.com. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article provides minimal detail beyond this announcement.
Form 4 Savara Inc For: 24 July By Investing.com
This article reports on a Form 4 filing for Savara Inc. dated July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders (directors, officers, or beneficial owners of more than 10% of a company's stock). The article itself contains no further details beyond stating the filing occurred and providing the company name and date.
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction
Savara Inc.'s Chief Financial and Operating Officer, Robert Lutz, recently acquired 70,000 stock options and 35,000 restricted stock units. This insider transaction signals the leadership's confidence in the company's future performance. The acquisition details are provided for investors monitoring insider activities.
Form 4 Savara Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Savara Inc. dated July 24. It briefly mentions the stock symbol SVRA, which showed a -4.17% change, and includes typical market data and financially related news.
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs
Savara Inc. (NASDAQ: SVRA) announced that its Chief Financial & Operating Officer, Robert Matthew Lutz, received equity awards on July 15, 2026. These awards include 35,000 restricted stock units (RSUs) vesting fully on July 15, 2028, and options for 70,000 shares with an exercise price of $5.81, vesting in 16 quarterly installments. Following these transactions, Lutz directly holds 328,977 shares of common stock and 70,000 stock options.
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 208 out of 386 in its industry. It highlights the company's P/E ratio of -9.87 and mentions that relevant data for P/B and P/CF ratios have not yet been disclosed. The stock closed at $5.510, down 4.17% on July 24, 2026.
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy
Savara Inc. stock is gaining traction as the company's inhaled lung therapy for pulmonary alveolar proteinosis approaches FDA review, backed by positive Phase 3 clinical trial data. While the company currently has limited commercial revenue, the potential approval of this lead product could significantly reshape its financial future. Investors are closely monitoring regulatory milestones, as the treatment aims to provide a less invasive alternative to current therapies for the rare lung condition.
If You Invested $1,000 in Savara Inc (SVRA)
This article analyzes the historical performance of investing $1,000 in Savara Inc (SVRA) over different timeframes, showing significant returns for 1 and 5-year periods but a loss since its trading inception in 2017. It also provides detailed information about Savara Inc, a biopharmaceutical company focused on rare respiratory diseases, particularly its lead program MOLBREEVI for autoimmune PAP, including its development status, regulatory designations, and commercialization preparations. The article further includes Savara Inc's year-by-year stock performance and compares its returns.
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16
Piper Sandler has reiterated its Buy rating for Savara (SVRA.US) and maintained its price target of $16. This indicates continued confidence in the company's stock performance from the analytical firm.
Here's Why You Should Add Savara Stock to Your Portfolio Now
Savara (SVRA) is highlighted as a strong buy due to the progress of its lead candidate, Molbreevi, for autoimmune pulmonary alveolar proteinosis (aPAP). The company has strong clinical data, is on track with regulatory milestones in the US, Europe, and the UK, and has expanded intellectual property protection. Savara currently holds a Zacks Rank #2 (Buy), with analysts narrowing loss per share estimates for 2026 and 2027.
Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Savara Inc. (SVRA) on behalf of shareholders who suffered losses due to alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements and concealed issues regarding its MOLBREEVI BLA, which is a treatment for pulmonary alveolar proteinosis, leading to regulatory approval delays and the need for additional capital. Shareholders affected during this period are encouraged to contact the firm to learn about their rights to recover losses.
Savara stock. Thin-source profile holds the focus.
Savara Inc. (SVRA) continues to focus on its rare-disease pipeline and Nasdaq listing, with its lead program being molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis. Despite the absence of new market catalysts, the company's development pipeline and financing profile remain central to its stock story. Investors primarily monitor trial data, regulatory updates, cash runway, and development timing changes.
Price to earnings forward of Savara, Inc. – NASDAQ:SVRA
This article displays the "Price to earnings forward" value for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the period value and change are displayed, and states that the information is "Made by humans."
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA
This article provides a financial snapshot for Savara, Inc. (NASDAQ: SVRA), focusing on its enterprise value to EBIT forward. It indicates whether there have been changes in this period and by what percentage. The data is supported by various financial services and is presented via TradingView.
Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA
This article displays the Enterprise Value to EBITDA forward for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point without further analytical text.
Savara Inc focuses on respiratory drug development as investors watch clinical progress
Savara Inc. is a clinical-stage biopharmaceutical company specializing in developing inhaled therapies for rare respiratory diseases. The company's strategy involves focusing on conditions with high unmet medical needs, pursuing orphan-drug designations, and advancing its pipeline through clinical trials. Investors closely monitor Savara's trial milestones, regulatory decisions, and financing activities, as the company's valuation is driven by expectations for clinical success rather than current revenue.
Price to book forward of Savara, Inc. – NASDAQ:SVRA
This article provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating the period and value of this metric. It originates from TradingView, a financial charting and analysis platform.
Price to sales forward of Savara, Inc. – NASDAQ:SVRA
This page provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its price-to-sales forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this particular financial ratio for the company.
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA
The article focuses on the enterprise value to revenue forward metric for Savara, Inc. (NASDAQ: SVRA). It appears to be a stub or a placeholder, as no specific financial data or analysis is presented in the provided content, only the title and navigation elements.
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline
Levi & Korsinsky LLP has announced a class action lawsuit against Savara Inc. (NASDAQ:SVRA), reminding investors of the November 7, 2025 deadline to join. The lawsuit alleges that Savara made false and misleading statements between March 4, 2024, and May 23, 2025, regarding the regulatory approval and chemistry, manufacturing, and controls of its drug MOLBREEVI, which impacted its stock value. Investors who suffered losses on their Savara Inc. shares during this period are encouraged to seek information about their recovery rights.
